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  ABSTRACT 
  To transcribe the treat-to-target (T2T) recommendations 
into a version that can be easily understood by patients. 
A core group of physicians and patients involved in the 
elaboration of the T2T recommendations produced a draft 
version of the T2T recommendations in lay language. This 
version was discussed, changed and reworded during 
a 1-day meeting with nine patients with rheumatoid 
arthritis (RA) from nine different European countries. 
Finally, the level of agreement with the translation and 
with the content of the recommendations was assessed 
by the patient participants. The project resulted in a 
patient version of the T2T recommendations. The level 
of agreement with the translation and the content was 
high. The group discussion revealed a number of potential 
barriers for the implementation of the recommendations 
in clinical practice, such as inequalities in arthritis 
healthcare provision across Europe. An accurate 
version of the T2T recommendations that can be easily 
understood by patients is available and can improve the 
shared decision process in the management of RA.       
  INTRODUCTION 
  In 2008, an international Steering Group of rheuma-
tologists and patients took the initiative to develop 
a set of recommendations for the tight control of 
rheumatoid arthritis (RA) patients (“treat-to-target,” 
T2T).    1    Clinical trial results over the last decade have 
demonstrated that strategies for tight control lead 
to better outcomes. These recommendations were 
developed in line with the European League Against 
Rheumatism (EULAR) standardised operational 
procedures,    2    including a comprehensive system-
atic literature review,    3    followed by a thorough data 
driven consensus process. The recommendations 
were extensively discussed during a 2-day meeting 
gathering more than 60 experts from different con-
tinents, including six patient representatives. They 
agreed on a set of four overarching principles and 
10 recommendations. Important components of 
these recommendations are target setting for drug 
treatment, regular monitoring of disease activity—
using composite measures, including joint counts—
and adjustment of treatment if the desired target is 
not achieved. 
  In October 2009, the implications of the recom-
mendations for clinical practice were discussed 
during a global T2T meeting. More than 25 physi-
cians from 22 countries and two patient delegates 
expressed the need for developing a patient version 
of the recommendations as a logical consequence 
of the ﬁ  rst overarching principle that emphasises 
the importance of a shared decision-making pro-
cess between the physician and the patient. The 
last recommendation states that this can only be 
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achieved if the patient is well informed about the 
different treatment options. As a follow-up on 
these statements, the Steering Group appointed a 
small working group with the objective to develop 
a patient version of the T2T recommendations as 
an important tool for patient education. 
  A patient version is important for several reasons. 
RA patients need to be appropriately informed 
about the potential beneﬁ  ts and harms of new phar-
macological treatments.    4     –      6    The technical nature of 
the medical language of recommendations is a bar-
rier for patients to understand their potential val-
ue.    7        8    Because drugs give the best outcomes when 
used according to a predeﬁ  ned regime, a proper 
understanding, acceptance and adherence are of 
utmost importance,    9    especially since some patients 
believe that the potential beneﬁ  ts do not outweigh 
the potential harms or personal preferences.    10     –      12    
Patient information that is understandable and 
written in lay language may enable them to make 
informed decisions about their treatment. It height-
ens patients’ satisfaction    5    and increases adherence 
to their treatment.    13    
  If patients are aware of the recommendations for 
the treatment of RA, and they know precisely how 
the treatment and monitoring should be organised 
according to these recommendations, they are able 
to start the dialogue with their rheumatologist. 
  Furthermore, a patient version might support 
physicians to engage the patient in the decision-
making process on an equal level. Finally, physi-
cians who are still reluctant to follow the T2T 
principles for their RA patients might be helped 
with a patient version to start this dialogue about 
the risks and beneﬁ  ts of tight control. The objective 
of the present study was to develop a patient ver-
sion of the T2T recommendations.   
  METHODS 
  The core group, consisting of four members of 
the international T2T Steering Group, including 
one patient representative (MPTdW), produced a 
draft version of the T2T recommendations in lay 
language. 
  This version was discussed, amended and 
reworded during a 1-day consensus meeting with 
nine RA patients and moderated by two mem-
bers of the core group (DMFMvdH, MPTdW). 
Recruitment and selection of participants was 
carried out with the help of the EULAR Standing 
Committee of Patients with Arthritis/Rheumatism 
in Europe and took place through purposive sam-
pling accounting for geographical variation, gen-
der and age. Participants should speak and read 
English. The core group made the ﬁ  nal selection. 
The group consisted of eight women and one 
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man, from nine countries representing all regions of Europe: 
Cyprus, Czech Republic, Denmark, Ireland, Norway, Portugal, 
The Netherlands, Romania and the UK. Age varied between 31 
and 66 years. Five participants were already involved in the T2T 
consensus meeting. 
  At the start of the meeting, the original recommendations 
were introduced and explained. Then, the draft patient version, 
developed by the core group, was shared with the participants. 
It was emphasised that the group was not allowed to make any 
changes in the content or meaning of the recommendations 
when developing the patient version. 
  Formulating a patient version in lay language was carried out 
by constantly comparing the original statements and the draft 
patient version. The consensus meeting was recorded. At the end 
of the meeting, the level of agreement with the translations as 
well as with the content was assessed by all patient participants, 
including the patient moderator, anonymously on a numerical 
rating scale ranging from 0 (no agreement) to 10 (full agreement). 
The group ﬁ  nally gave suggestions for implementation.   
  RESULTS 
  Statements 
  The patient version of the recommendations is presented 
in   table   1  . The group tried to stay as close as possible to the 
  original meaning. Sometimes, simpliﬁ  cation was achieved by 
cutting long sentences in multiple short sentences. At other 
moments, the group looked for common synonyms or clariﬁ  ca-
tion in lay language. Long discussions took place concerning the 
translation and the value of the words “signiﬁ  cant” and “vali-
dated.” Finally, the group decided on different solutions, and 
this kept the word signiﬁ  cant and proposed that each country 
should explore synonyms or translations in their own language. 
For the word validated, many synonyms were brought forward, 
but in no cases did this capture the meaning of the word. At the 
end, the term was not seen as a crucial element to understand 
the message of the recommendation. The decision was made to 
delete the word.   
  To avoid long sentences in the patient version, the group iden-
tiﬁ  ed other words and concepts that should be explained in the 
accompanying text and suggested words for the glossary (see 
  table 2  ).     
    Evaluation of the patient version 
  The patient group, including the patient moderator, emphasised 
the importance of the recommendations (mean level of agree-
ment with the content: 9.3; see   ﬁ  gure 1  ). The group was con-
vinced that patients would beneﬁ  t greatly from a patient version 
that informs them about the treatment regime that they receive, 
or empowers people with RA who do not receive treatment 
according to these recommendations.   
  Table  1         Original and patient version of the treat-to-target (T2T) recommendations for treating rheumatoid arthritis (RA) to target    
 Original   Patient  version 
Overarching T2T principles
(A)    The treatment of RA must be based on a   shared decision   between patient and 
rheumatologist
(A)    Decisions regarding the treatment of RA must be made by the patient and 
rheumatologist together.
(B)    The primary goal of treating the patient with RA is to maximise long-term 
health-related quality of life through control of symptoms, prevention of 
structural damage, normalisation of function and social participation
(B)    The most important goal of treatment is to maximise long-term   health-related 
quality of life  . This can be achieved through
  control of disease symptoms like pain, inﬂ  ammation, stiffness and fatigue;
  prevention of damage to joints and bones;
 regaining    normal function   and   participation   in daily-life activities.
(C)  Abrogation of inﬂ  ammation is the most important way to achieve these goals (C)  The most important way to achieve these goals is to stop joint   inﬂ  ammation 
(D)    Treatment to target by measuring disease activity and adjusting therapy 
accordingly optimises   outcomes   in RA
(D)    Treatment toward a clear   target   of   disease activity   gives the best results in RA. 
This can be achieved by measuring disease activity and   adjusting therapy   if the 
target is not achieved.
Recommendations
(1)  The primary target for treatment of RA should be a state of clinical remission (1)  The primary target of treatment of RA should be   clinical remission 
(2)    Clinical remission is deﬁ  ned as the absence of signs and symptoms of 
signiﬁ  cant inﬂ  ammatory disease activity
(2)    Clinical remission means that   signiﬁ  cant signs   and   symptoms   of the disease that 
are caused by inﬂ  ammation are absent
(3)    While remission should be a clear target, based on available evidence low 
disease activity may be an acceptable alternative therapeutic goal, particularly 
in established, longstanding disease
(3)   Although    remission   should be the target, it is not possible for some patients, in 
particular for those with long disease duration. Therefore,   low disease activity  
may be an acceptable alternative.
(4)    Until the desired treatment target is reached, drug therapy should be adjusted 
at least every 3 months
(4)    Until the desired treatment target is reached, drug therapy should be   adjusted   at 
least every 3 months
(5)    Measures of disease activity must be obtained and documented regularly, as 
frequently as monthly for patients with high/moderate disease activity or less 
frequently (such as every 3–6 months) for patients in sustained low disease 
activity or remission
(5)    Disease activity must be measured and documented regularly. For patients with 
  high   or   moderate disease activity   this must be done every month. For patients 
in a   sustained   low disease activity state or remission, this can be done less 
frequently (eg, every 3–6 months).
(6)    The use of   validated composite measures   of disease activity, which include 
joint assessments, is needed in routine clinical practice to guide treatment 
decisions
(6)    Combined disease activity   measurements   which include joint examinations are 
needed in routine clinical practice to guide treatment decisions
(7)     Structural changes   and   functional impairment   should be considered when 
making clinical decisions, in addition to assessing composite measures of 
disease activity
(7)    Besides disease activity treatment decisions in clinical practice should also 
consider damage to the joints and restrictions in activities of daily living
(8)    The desired treatment target should be maintained throughout the remaining 
course of the disease
(8)    The desired treatment target should be maintained throughout the remaining 
course of the disease
(9)    The choice of the (composite) measure of disease activity and the level of the 
target value may be inﬂ  uenced by considerations of   comorbidities ,  patient 
factors and drug related risks
(9)    Selecting the appropriate measurement of disease activity and target may be 
inﬂ  uenced by the individual situation: presence of other diseases,   patient related 
factors   or drug-related safety risks
(10)   The patient has to be appropriately informed about the treatment target and the 
strategy planned to reach this target under the supervision of the rheumatologist
(10)   The patient has to be appropriately informed about the treatment target and the 
  strategy   planned to reach this target under the supervision of the rheumatologist
      Italic words are explained in the glossary (see   table 2  ). Bold words are explained in   table 3  .     
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  Implementation 
  The patient group assumed that currently only a few patients 
are being treated according to these recommendations and that 
there is a substantial gap between daily practice and the recom-
mended treatment strategy. The recommendations reﬂ  ect the 
ideal world; many clinicians are aware of the importance but are 
confronted with barriers for implementation, and compliance is 
poor. The patient group also identiﬁ  ed differences in healthcare 
delivery across Europe. Therefore, improvement of health-
care for people with RA requires thoughtful implementation 
of the recommendations. This patient version has been devel-
oped by experienced patient representatives ﬂ  uent in English. 
The patient version has not yet been validated in a group of 
lay patients. Translation into different languages and testing the 
recommendations in different countries were seen as important 
subsequent steps in this process. 
  Dissemination of a patient version, leaﬂ  et or booklet could 
make patients aware of what constitutes good disease manage-
ment for them: how often should they see their   rheumatologist, 
what should they expect from the consult, what is their involve-
ment in the decision-making process, and what should they 
expect from the treatment? In this respect, the perception and 
understanding of the target are important factors that need 
more consideration. A clear and uniform target in other diseases 
  Table  2         Glossary of terms in lay language, in alphabetical order   
  Terms    Explanation in lay language   No* 
Adjustment of drug treatment A change to the drug treatment has to be made. This is not always necessarily a change in drug. For patients 
who have not achieved the primary target of remission but show signiﬁ  cant improvement over the last 3 months, 
dose adaptation or continuation for several weeks instead of change of drug(s) may be sufﬁ  cient. The kind of 
adjustment depends on the applied strategy and individual response of the patient.
D, 4
Clinical remission Clinical remission is based on the complaints by the patient, examination of the joints and results of laboratory tests. 
This can be done by the rheumatologist using a variety of instruments that measure disease activity (see   table 3  ). 
When the score is below a set value, the patient is in a state of remission. Clinical remission does not incorporate 
radiographic, MRI, ultrasound or other imaging outcomes.
1, 2
Comorbidity The existence of two or more (chronic) diseases in one person at the same time—for example, a patient with RA 
and diabetes mellitus or RA and hypertension
9
Composite measure Measurement instrument that combines different aspects of the disease into a single numerical value. Examples of 
composite measures for disease activity in RA are: Clinical Disease Activity Index, Simpliﬁ  ed Disease Activity Index, 
Disease Activity Score and Disease Activity Score 28 joint count.
6, 7, 8
Disease activity Signs and symptoms caused by inﬂ  ammation owing to RA. Rheumatologists use cut-off points to delineate different 
levels of disease activity. They often distinguish between four states of disease activity: high, moderate, low or remission. 
A common deﬁ  nition of these four states is currently not available; the deﬁ  nition depends on the instrument that is used 
(see   table 3  ).
D, 2, 3, 5, 6
Functional impairment The impact of the disease on performing tasks in daily life 7
Health-related Quality of Life   Health-related   quality of life is key in this statement. Quality of life is determined by a variety of individual and social 
factors. Health-related quality of life refers directly to the impact of the disease on daily life. It is not limited to the 
medical encounters in the clinic. It includes the impact of the disease on psychological health, work participation, 
family life, social relationships and leisure.
B
Inﬂ  ammation Inﬂ  ammation is the basis of the disease process in RA. It is caused by immune system cells and their products 
(cytokines), and leads directly to signs and symptoms, such as joint swelling, pain and stiffness. It also results in 




The assessment of a particular health-related factor by using the most appropriate instrument (eg, test or questionnaire) 5, 6, 7, 9
Normal function Normalisation of function is trying to return to normality: the state where a person was before the disease started 7
Outcome The effect (end result) of the disease process on the patient or the effect of a treatment on a patient, which may 
be measured in different ways. Patient-related outcomes are based on the experience or opinion by the patient, and 
include, for example, pain, fatigue and physical function. Objective measures (outcomes) are independent of the 
opinion of the patient—for example, radiological joint damage (x rays) or blood tests (signs of inﬂ  ammation such as 
sedimentation rate or C reactive protein). The term “optimising outcomes” means trying to achieve the “best end results.”
D
Patient factors Patient factors relates to personal preferences and characteristics such as occupation, age or gender 9
Remission A state of disease activity without any signiﬁ  cant signs of inﬂ  ammation 1, 2, 3, 4
Shared decision-making The process by which the physician and the patient take a decision together, based on a dialogue about the preferences 
of the patient and the knowledge (“evidence”) of the physician. A condition for shared decision-making is an equal 
partnership in the patient–doctor relation.
A
Signiﬁ  cant “Signiﬁ  cant” might be translated into other languages with synonyms such as important, serious, most, crucial or 
relevant. “Signiﬁ  cant” is a relative term and often causes discussion, depending on the context and the individual 
perspective. In research, an outcome is   statistically   signiﬁ  cant if it is unlikely that the outcome has occurred by 
chance (eg, a signiﬁ  cant change in pain on a new drug).   Clinical   signiﬁ  cance refers to an individual appreciation of an 
improvement in the real world: is an improvement really important from the perspective of the patient?
2
Signs Signs are the manifestations that can be observed by physical examination, such as the number of swollen joints 2
Social participation The ability to contribute to society or to enjoy social life. Functional limitations can seriously restrict chances of 
participation in daily-life activities.
B, 7
Strategy A predeﬁ  ned way by which the clinician and the patient try to achieve the treatment target D, 10
Structural damage The destruction of bones and joints, as can be detected using imaging techniques such as x rays, MRI or sonography. 
This is caused by inﬂ  ammation and is largely irreversible.
B, 7
Sustained remission A state of remission that is maintained during a longer period of time—for example, more than 6 months 5
Symptoms Symptoms are manifestations of the disease as they are felt or experienced by the patient like fatigue, pain or stiffness 2
Target Ultimate goal; the ﬁ  nal outcome you want to achieve by treating RA passim
Validated measurement 
instrument
An instrument (method, questionnaire, test) that has been scientiﬁ  cally proven to measure what it supposes to 
measure in a particular disease
6
      *The third column indicates the treat-to-target statements where the original term is used. The letters A–D refer to the overarching principles, and the ciphers 1–10 refer to the 
recommendations. 
 RA,  rheumatoid  arthritis.   
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has been successfully identiﬁ  ed and implemented for diabetes, 
hyperlipidaemia and hypertension.    1    A similar uniform value is 
not available for RA. Rheumatologists use different measure-
ments and a different terminology for disease activity,    14    which 
complicates education of patients and a clear dialogue about the 
treatment target. As long as a simple and worldwide-accepted 
indicator for disease activity is lacking, the group felt it neces-
sary to provide a clear overview of deﬁ  nitions used for high, 
moderate and low disease activity and remission (see   table 3  ).   
  A recent initiative by American College of Rheumatology and 
EULAR resulted in two proposals for more stringent criteria for 
remission in clinical trials    15     : one is a Boolean-based deﬁ  nition 
encompassing tender joint count ≤1 AND swollen joint count 
≤1 AND C reactive protein (CRP) ≤1 mg/dl AND patient global 
assessment ≤1 (on a 0–10 scale). The other deﬁ  nition is the index-
based Simpliﬁ  ed Disease Activity Index ≤3.3 (  table 3  ). For use in 
clinical practice, both deﬁ  nitions are suggested without CRP.     
  DISCUSSION 
  Development of a patient version of a set of recommendations is 
currently not a common activity, and in the ﬁ  eld of rheumatology 
two initiatives have been published to incorporate the patient 
perspective in an international project. For the patient version 
of the ASAS/EULAR recommendations for the management 
of ankylosing spondylitis,    16    18 patient representatives from 10 
countries were invited for a 2-day consensus meeting. They not 
only translated the original recommendations in lay language,    17    
but also extensively discussed the content of the recommenda-
tions and produced a wish list from a patient’s perspective to be 
discussed when the recommendations are updated. 
  A similar endeavour was undertaken by the task force 
for the development of EULAR recommendations on the 
management of systemic glucocorticoid therapy in rheumatic 
diseases.    18    Using different methods, they explored the per-
spectives of patients and rheumatologists on glucocorticoid 
therapy in order to enhance the implementation of the recom-
mendations. Although they did not produce a patient version, 
patient participants did provide ideas for improving the imple-
mentation of the recommendations and a research agenda.    19    
They conclude that patients’ and rheumatologists’ perspec-
tives should be included early in the process of formulating 
recommendations. 
  The T2T patient group indicated that, according to a holistic 
approach of arthritis healthcare, drug treatment is an important, 
but not the only, component that determines clinical outcomes. 
The participants noticed that the T2T recommendations, like 
the EULAR/ASAS recommendations, have a strong focus on 
body functions and structures, while patient-centred care in 
rheumatology also requires, besides medical expertise and 
monitoring, non-pharmacological and psychosocial support.    20    
In this regard, the group emphasised the importance of multi-
disciplinary teamwork in the management of RA, because in 
carrying out the scores and in educating and empowering the 
patient to actually engage in shared decision-making with rheu-
matologists, they need support from other key professionals. 
Although nurse practitioners and physician assistants could be 
ideally positioned to educate RA patients regarding treatment 
options and to monitor disease activity,    21    they are not available 
in many countries. 
  The patients reported from their experiences that they cannot 
absorb all the information provided, speciﬁ  cally at the ﬁ  rst visit 
to a rheumatologist. A meeting with a specialised nurse could 
be very useful. Because it is crucial to start treatment as soon 
as possible after the diagnosis is made, patients should receive 
information about the risks of the disease and the expected 
outcomes of the treatment. To be effective, the patient should 
adhere to the drug strategy, and this can only be achieved if 
the patient is well informed and accepts the consequences of 
the strategy. A patient version is very useful to support this 
process. 
  In contrast to the EULAR/ASAS patient version, the partici-
pants did not disagree with the content of any of the recom-
mendations and, in contrast to the glucocorticoid patient group, 
did not add any topics to the research agenda. This might 
be because some patient representatives were also actively 
involved at different levels in the development process of the 
original recommendations. In the ﬁ  nal discussion, however, the 
group mentioned barriers for implementation. Above all, they 
referred to the limited access to rheumatology care. It is not in 
every country that RA patients see their rheumatologist every 
3  months or more often, the doctor’s time is restricted, and joint 
assessments are not regularly carried out, properly documented 
or provided to the patient. In a majority of countries, people do 
not have access to their own data. There are advanced digital 
registration systems available that allow for regular reports on 
  Table  3         Validated composite measures and their cut-off points for different states of disease activity   
 Composite  measure 
(number of components) 
 Clinical  Disease 
Activity 
Index   23      24     (4) 
 Simpliﬁ  ed 
Disease Activity 
Index   23      24     (5) 
  Disease Activity Score 
based on 44 joint 
counts   25     (5) 
  Disease Activity Score 
based on 28 joint 
counts   26     (5) 
High disease activity >22 >26 >3.7 >5.1
Moderate disease activity >10–22 >11–26 >2.4–3.7 >3.2–5.1
Low disease activity >2.8–10 >3.3–11 ≥ 1.6–2.4 ≥ 2.6–3.2
Remission ≤ 2.8 ≤ 3.3  *  <1.6 <2.6
    *  American College of Rheumatology–European League Against Rheumatism preliminary deﬁ  nition of remission for clinical trials.   15     
  Figure  1        Level of agreement with the overarching principles A–D and 
the recommendations 1–10 according to the patient representatives 
(n=10). The level of agreement (indicated on the y-axis) was measured 
on a 10-point numerical rating scale with the highest number (10) 
representing “full agreement” and the lowest number (1) “no agreement 
at all.” The black bars represent the level of agreement with the 
translation in lay language, and the grey bars represent the level of 
agreement  with  the  content.      
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disease activity, management, monitoring, patient education 
and   self-management.    22    Some are also accessible for patients 
who can monitor their own disease using the internet from 
home, but such use is not widespread. 
  The group thought that there is also a role for patient organi-
sations to use the patient version of the T2T recommendations 
to approach politicians, regulators and healthcare payers in 
their country. They could make a claim for better legislation 
that is in agreement with widely accepted recommendations 
to guarantee better access to appropriate treatment strate-
gies, good healthcare information and programmes for self-
  management, ﬁ  nally resulting in better health outcomes for 
people with RA.     
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